DNA hypermethylation status of multiple genes in papillary thyroid carcinomas

Pathobiology

Volumn 74, Issue 6, 2007, Pages 344-352

  Ishida, Eiwa ^a   Nakamura, Mitsutoshi ^a   Shimada, Keiji ^a   Higuchi, Tomonori ^a   Takatsu, Keisuke ^b   Yane, Katsunari ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Chronic inflammation; Homozygous deletion; Methylation; Papillary thyroid carcinoma

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P14ARF; PROTEIN P16INK4A; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CHRONIC DISEASE; CONTROLLED STUDY; DNA HYPERMETHYLATION; DNA METHYLATION; FEMALE; GENE DELETION; HOMOZYGOSITY; HUMAN; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MUTATION; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHOOL CHILD; THYROID CARCINOMA; THYROID DISEASE; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; CARCINOMA, PAPILLARY; CHILD; CPG ISLANDS; DNA METHYLATION; FEMALE; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 37249077105     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110028     Document Type: Article

References (45)

1. Ward LS, Brenta G, Medvedovic M, Fagin JA: Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab 1998;83:525-530.
2. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G: PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-563.
3. Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, Pilotti S, Fusco A, Della Porta G, Pierotti MA: Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 1994;54:2979-2985.
4. Wajjwalku W, Nakamura S, Hasegawa Y, Miyazaki K, Satoh Y, Funahashi H, Matsuyama M, Takahashi M: Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res 1992;83:671-675.
5. Motomura T, Nikiforov YE, Namba H, Ashizawa K, Nagataki S, Yamashita S, Fagin JA: Ret rearrangements in Japanese pediatric and adult papillary thyroid cancers. Thyroid 1998;8:485-489.
6. Kitamura Y, Minobe K, Nakata T, Shimizu K, Tanaka S, Fujimori M, Yokoyama S, Ito K, Onda M, Emi M: Ret/ptc3 is the most frequent form of gene rearrangement in papillary thyroid carcinomas in Japan. J Hum Genet 1999;44:96-102.
7. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of braf mutations in thyroid cancer: genetic evidence for constitutive activation of the ret/ptc-ras-braf signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
8. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-4580.
9. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-262.
10. Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K: The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog 2007;46:242-248.
11. Wojciechowska K, Lewinski A: BRAF mutations in papillary thyroid carcinoma. Endocr Regul 2006;40:129-138.
12. Elisei R, Shiohara M, Koeffler HP, Fagin JA: Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15ink4b and p16ink4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 1998;83:2185-2193.
13. Konishi N, Hiasa Y, Matsuda H, Tao M, Tsuzuki T, Hayashi I, Kitahori Y, Shiraishi T, Yatani R, Shimazaki J, et al: Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol 1995;147:1112-1122.
14. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
15. Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H: Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 2001;81:77-82.
16. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, Kleihues P, Ohgaki H: p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001;11:159-168.
17. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-797.
18. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
19. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB, Herman JG: Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-2371.
20. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE: Loss of pRB expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000;60:1211-1216.
21. ink4a genes in primary central nervous system lymphomas. Cancer Res 2001;61:6335-6339.
22. Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E, Shimada K: DNA hypermethylation status of multiple genes in prostate adenocarcinomas. Jpn J Cancer Res 2002;93:767-773.
23. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG: Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000;60:129-133.
24. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD, Yang CS: Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999;5:2704-2713.
25. Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E, Shimada K: Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol 2002;160:1207-1214.
26. Svensson S, Nilsson K, Ringberg A, Landberg G: Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 2003;63:1737-1742.
27. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
28. Yaginuma Y, Hayashi H, Kawai K, Kurakane T, Saitoh Y, Kitamura S, Sengoku K, Ishikawa M: Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines. Exp Cell Res 1997;233:233-239.
29. Anwar F, Emond MJ, Schmidt RA, Hwang HC, Bronner MP: Retinoblastoma expression in thyroid neoplasms. Mod Pathol 2000;13:562-569.
30. Holm R, Nesland JM: Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 1994;172:267-272.
31. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, et al: Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994;91:11045-11049.
32. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95:8292-8297.
33. Nickeleit I, Zender S, Kossatz U, Malek NP: p27kip1: a target for tumor therapies? Cell Div 2007;2:13.
34. Bugni JM, Han J, Tsai MS, Hunter DJ, Samson LD: Genetic association and functional studies of major polymorphic variants of MGMT. DNA Repair (Amst) 2007;6:1116-1126.
35. Resnick MB, Schacter P, Finkelstein Y, Kellner Y, Cohen O: Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod Pathol 1998;11:735-739.
36. Karlidag T, Cobanoglu B, Keles E, Alpay HC, Ozercan I, Kaygusuz I, Yalcin S, Sakallioglu O: Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol 2007;28:31-36.
37. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS: Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003;163:1551-1556.
38. Sato F, Harpaz N, Shibata D, Xu Y, Yin J, Mori Y, Zou TT, Wang S, Desai K, Leytin A, Selaru FM, Abraham JM, Meltzer SJ: Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 2002;62:1148-1151.
39. Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, Matsuzuka F, Kakudoh K, Kuma K, Tamai H: The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab 1995;80:3421-3424.
40. Kashima K, Yokoyama S, Noguchi S, Murakami N, Yamashita H, Watanabe S, Uchino S, Toda M, Sasaki A, Daa T, Nakayama I: Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 1998;8:197-202.
41. Gupta S, Patel A, Folstad A, Fenton C, Dinauer CA, Tuttle RM, Conran R, Francis GL: Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J Clin Endocrinol Metab 2001;86:1346-1354.
42. Santoro M, Melillo RM, Fusco A: RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 2006;155:645-653.
43. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A: RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995;11:1207-1210.
44. Rebelo S, Domingues R, Catarino AL, Mendonca E, Santos JR, Sobrinho L, Bugalho MJ: Immunostaining and RT-PCR: different approaches to search for RET rearrangements in patients with papillary thyroid carcinoma. Int J Oncol 2003;23:1025-1032.
45. Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, Sidransky D: Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 2004;64:1664-1668.